Cancer Research Institute Inc
Cancer Research Institute Inc maintains stable assets despite fluctuating revenues and reports 0% officer compensation.
EIN: 131837442 · New York, NY · NTEE: H300 · Updated: 2026-03-28
| Metric | Value |
|---|---|
| Total Revenue | $54.0M |
| Total Expenses | $38.6M |
| Program Spending | 80% |
| CEO/Top Officer Pay | $53,967,271 |
| Net Assets | $68.0M |
| Transparency Score | 85/100 |
Is Cancer Research Institute Inc Legit?
Some Concerns
Assessment based on IRS 990 filings, spending patterns, and AI analysis. Not a guarantee of legitimacy. Full charity check →
Cancer Research Institute Inc directs 80% of its spending to programs. This exceeds the industry benchmark of 65%, indicating strong mission focus.
About Cancer Research Institute Inc
Cancer Research Institute Inc (EIN: 131837442) is a nonprofit organization based in New York, NY, classified under NTEE code H300. The organization reported total revenue of $54.0M and total assets of $133.7M according to its most recent IRS 990 filing. This transparency report provides an AI-powered analysis of Cancer Research Institute Inc's financial health, spending patterns, executive compensation, and overall mission effectiveness based on publicly available IRS data.
Organization Overview
Cancer Research Institute Inc is a major nonprofit that has been operating for 73 years, with 12 years of IRS 990 filings on record (2012–2023). Revenue has grown at a compound annual rate of 6.7%.
Key Financial Metrics (2023)
From the most recent IRS 990 filing on record:
| Total Revenue | $32.3M |
| Total Expenses | $38.6M |
| Surplus / Deficit | $-6,257,404 |
| Total Assets | $138.0M |
| Total Liabilities | $70.0M |
| Net Assets | $68.0M |
| Operating Margin | -19.4% |
| Debt-to-Asset Ratio | 50.7% |
| Months of Reserves | 43.0 months |
Financial Health Grade: C
In 2023, Cancer Research Institute Inc reported a deficit of $6.3M with expenses exceeding revenue, holds 43.0 months of operating reserves (strong position), has a debt-to-asset ratio of 50.7% (high leverage).
Financial Trends
Over 12 years of filings (2012–2023), Cancer Research Institute Inc's revenue has grown at a compound annual growth rate (CAGR) of 6.7%.
| Year | Revenue Change | Expense Change | Asset Change |
|---|---|---|---|
| 2023 | -4.1% | +23.1% | +5.8% |
| 2022 | -6.4% | -15.7% | -11.0% |
| 2021 | -3.3% | -3.5% | +15.8% |
| 2020 | -11.4% | +10.8% | -0.8% |
| 2019 | +66.6% | +16.5% | +14.1% |
IRS Tax-Exempt Classification
| IRS Classification Codes | 1000 |
| IRS Ruling Date | 1953 |
Classification data from ProPublica Nonprofit Explorer. Additional BMF data may be available after enrichment.
AI Transparency Report
Mission Effectiveness Score
NonprofitSpending's AI analysis rates Cancer Research Institute Inc with a Mission Score of 85 out of 100 (Excellent). This score reflects the organization's overall financial transparency, program spending efficiency, and governance indicators derived from IRS 990 public filings.
Spending Breakdown
- admin: 10%
- programs: 80%
- fundraising: 10%
According to IRS 990 filings, Cancer Research Institute Inc allocates its expenses as follows: admin: 10%, programs: 80%, fundraising: 10%. With 80% directed toward programs, this reflects a strong commitment to its charitable mission.
Key Financial Metrics (2023)
From the most recent IRS 990 filing on record:
- The organization reported a deficit of $6.3M, with expenses exceeding revenue.
- Debt-to-asset ratio: 50.7%.
Executive Compensation Analysis
The reported 0% officer compensation across all available filings is highly unusual for an organization of this size ($53,967,271 latest revenue, $133,734,670 assets), suggesting that executive compensation may be reported under different categories or is genuinely very low, which enhances financial efficiency.
Executive compensation data is sourced from IRS 990 filings, which require nonprofits to disclose the compensation of officers, directors, trustees, and key employees. NonprofitSpending analyzes this data relative to the organization's total revenue and sector benchmarks to assess whether executive pay is reasonable.
Red Flags
The following concerns were identified during AI analysis of Cancer Research Institute Inc's IRS 990 filings:
- Fluctuating revenue makes long-term financial planning challenging.
- 0% officer compensation reported is unusual and warrants further scrutiny into other compensation categories to ensure full transparency.
Strengths
The following positive indicators were identified for Cancer Research Institute Inc:
- Strong asset base consistently exceeding liabilities ($138,008,864 assets vs. $70,013,010 liabilities in 2023).
- Consistent reporting of 0% officer compensation, indicating potential efficiency or alternative compensation structures.
- Mission alignment with NTEE code H300 (Medical Research).
Frequently Asked Questions about Cancer Research Institute Inc
Is Cancer Research Institute Inc a legitimate charity?
Cancer Research Institute Inc (EIN: 131837442) is a registered tax-exempt nonprofit based in New York. Our AI analysis gives it a Mission Score of 85/100. It has 12 years of IRS 990 filings on record. Total revenue: $54.0M. 2 red flags identified. 3 strengths noted. Financial health grade: C.
How does Cancer Research Institute Inc spend its money?
Cancer Research Institute Inc directs 80% of its spending to programs and services. Fundraising costs 10%. This exceeds the 65% industry benchmark.
Are donations to Cancer Research Institute Inc tax-deductible?
Cancer Research Institute Inc is registered as a tax-exempt nonprofit (EIN: 131837442). Donations to most 501(c)(3) organizations are tax-deductible. Consult a tax professional for your specific situation.
How much does the Cancer Research Institute Inc CEO make?
Cancer Research Institute Inc's highest-compensated officer earns $53,967,271 annually. The organization reported $54.0M in total revenue. Executive compensation data is disclosed in IRS 990 filings.
What percentage of Cancer Research Institute Inc's spending goes to programs?
Cancer Research Institute Inc directs 80% to programs, 10% to fundraising. This exceeds the 65% industry benchmark for efficient nonprofits.
How does Cancer Research Institute Inc compare to similar nonprofits?
With a transparency score of 85/100 (Excellent), Cancer Research Institute Inc is above average for NTEE category H300 nonprofits. The score reflects financial transparency, program spending efficiency, and governance quality based on IRS 990 data.
Where is Cancer Research Institute Inc located?
Cancer Research Institute Inc is headquartered in New York, New York and files with the IRS under EIN 131837442. It is classified under NTEE code H300.
How many years of IRS 990 filings does Cancer Research Institute Inc have?
Cancer Research Institute Inc has 12 years of IRS 990 filings on record at NonprofitSpending. This extensive filing history provides a strong basis for evaluating long-term financial trends. The most recent filing shows $54.0M in total revenue.
Is Cancer Research Institute Inc a good charity?
Based on the available data, the Cancer Research Institute Inc appears to be a good charity. It maintains a strong asset base, consistently reports 0% officer compensation, and its mission aligns with its NTEE code. Further investigation into detailed program spending and other compensation lines would provide a more complete picture.
How has the organization's revenue trended over the past decade?
The organization's revenue has fluctuated significantly over the past decade, ranging from a low of $24,905,501 in 2017 to a high of $46,760,046 in 2014, with the latest reported revenue at $32,295,259 in 2023.
What is the organization's financial stability?
The organization demonstrates good financial stability, with assets consistently exceeding liabilities. In 2023, assets were $138,008,864 against liabilities of $70,013,010, indicating a healthy financial cushion.
Filing History
IRS 990 filing history for Cancer Research Institute Inc showing financial trends over 12 years of public records:
Over 12 years of IRS 990 filings (2012–2023), Cancer Research Institute Inc's revenue has grown by 104.5%, moving from $15.8M to $32.3M. Total assets increased by 170.4% over the same period, from $51.0M to $138.0M. Total functional expenses rose by 140.4%, from $16.0M to $38.6M. In its most recent filing year (2023), Cancer Research Institute Inc reported a deficit of $6.3M, with expenses exceeding revenue. The organization holds $70.0M in liabilities against $138.0M in assets (debt-to-asset ratio: 50.7%), resulting in net assets of $68.0M.
| Year | Revenue | Expenses | Assets | Liabilities | Officer Comp. % | |
|---|---|---|---|---|---|---|
| 2023 | $32.3M | $38.6M | $138.0M | $70.0M | — | View 990 |
| 2022 | $33.7M | $31.3M | $130.4M | $63.7M | — | View 990 |
| 2021 | $36.0M | $37.1M | $146.5M | $72.1M | — | View 990 |
| 2020 | $37.2M | $38.5M | $126.6M | $66.2M | — | View 990 |
| 2019 | $42.0M | $34.7M | $127.6M | $68.8M | — | View 990 |
| 2018 | $25.2M | $29.8M | $111.8M | $59.6M | — | View 990 |
| 2017 | $24.9M | $24.7M | $110.1M | $55.4M | — | View 990 |
| 2016 | $45.0M | $31.2M | $110.8M | $57.1M | — | View 990 |
| 2015 | $27.7M | $38.7M | $96.3M | $51.4M | — | View 990 |
| 2014 | $46.8M | $25.9M | $87.2M | $34.4M | — | View 990 |
| 2013 | $20.0M | $18.6M | $58.8M | $31.0M | — | View 990 |
| 2012 | $15.8M | $16.0M | $51.0M | $26.5M | — | View 990 |
Year-by-Year Financial Summary
- 2023: Revenue of $32.3M, expenses of $38.6M, and assets of $138.0M (revenue -4.1% year-over-year).
- 2022: Revenue of $33.7M, expenses of $31.3M, and assets of $130.4M (revenue -6.4% year-over-year).
- 2021: Revenue of $36.0M, expenses of $37.1M, and assets of $146.5M (revenue -3.3% year-over-year).
- 2020: Revenue of $37.2M, expenses of $38.5M, and assets of $126.6M (revenue -11.4% year-over-year).
- 2019: Revenue of $42.0M, expenses of $34.7M, and assets of $127.6M (revenue +66.6% year-over-year).
- 2018: Revenue of $25.2M, expenses of $29.8M, and assets of $111.8M (revenue +1.2% year-over-year).
- 2017: Revenue of $24.9M, expenses of $24.7M, and assets of $110.1M (revenue -44.7% year-over-year).
- 2016: Revenue of $45.0M, expenses of $31.2M, and assets of $110.8M (revenue +62.4% year-over-year).
- 2015: Revenue of $27.7M, expenses of $38.7M, and assets of $96.3M (revenue -40.7% year-over-year).
- 2014: Revenue of $46.8M, expenses of $25.9M, and assets of $87.2M (revenue +133.4% year-over-year).
- 2013: Revenue of $20.0M, expenses of $18.6M, and assets of $58.8M (revenue +26.9% year-over-year).
- 2012: Revenue of $15.8M, expenses of $16.0M, and assets of $51.0M.
View Individual Filing Years
Explore detailed financial data from each IRS 990 filing year for Cancer Research Institute Inc:
Data Sources and Methodology
This transparency report for Cancer Research Institute Inc is generated by NonprofitSpending's AI analysis engine. The data is sourced from publicly available IRS 990 filings accessed through the ProPublica Nonprofit Explorer API and IRS electronic filing records. The Mission Score, spending breakdown, and other analytical insights are produced by artificial intelligence and should be used as one of multiple factors when evaluating a nonprofit organization.
IRS 990 forms are annual information returns that most tax-exempt organizations must file with the IRS. These forms provide detailed financial information including revenue, expenses, assets, liabilities, and compensation of officers. NonprofitSpending processes this data to provide accessible transparency reports for donors, researchers, and the general public.
Disclaimer
AI-generated analysis based on IRS public records. Not financial or legal advice. Verify information directly with the organization.